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Abstract The E2F family of transcription factors plays a piv-
otal role in the regulation of cell proliferation and their activity
is often deregulated in human tumors. Recent studies demon-
strate that E2F1 can induce both proliferation and apoptosis.
E2F1-induced apoptosis occurs via multiple pathways, some of
which induce stabilization and activation of the tumor suppres-
sor p53. The pro-apoptotic activity of E2F1 suggests that its
deregulation constitutes an oncogenic stress that may target
pre-malignant cells to undergo apoptosis, thus preventing tumor
development. # 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The E2F family of transcription factors comprises six struc-
turally related E2Fs (E2F1^6) that function as heterodimers
with members of the DP family (DP-1 and DP-2). Initial
studies implicated E2F/DP heterodimers mainly in transcrip-
tional activation of genes required for cell cycle progression.
However, it is currently clear that transcriptional activation of
cell cycle-related genes is only one facet of E2F activity: data
accumulated over the last few years demonstrate that E2Fs
function in both transactivation and repression of gene ex-
pression. Furthermore, it is now clear that E2Fs have impor-
tant roles in regulating both cell proliferation and antipro-
liferative processes such as apoptosis and senescence.
E2F transcriptional activity is modulated by multiple mech-
anisms, including negative regulation by interaction with the
product of the Rb tumor suppressor gene, pRB, and its re-
lated proteins p107 and p130, collectively referred to as pocket
proteins (reviewed in [1]). This association not only inhibits
E2F-induced transactivation but also actively represses tran-
scription upon interaction of the E2F-associated pocket pro-
teins with histone deacetylases (HDACs), hSWI/SNF nucleo-
some remodeling complex, and polycomb group proteins [2].
Formation of pocket proteins/E2F containing complexes is
cell cycle-regulated. Speci¢cally, cyclins expressed at the G1-
phase of the cell cycle positively regulate their associated ki-
nases, the cyclin-dependent kinases (Cdk), which phosphory-
late the pocket proteins [3,4], resulting in sequential dissocia-
tion of HDAC/RB/E2F complexes. This leads to derepression
as well as activation of E2F-regulated genes and an ensuing
S-phase entry. Deregulated E2F activity occurs in the majority
of human tumors, via a number of di¡erent mechanisms.
These include: functional loss of pRB, the negative regulator
of E2F activity; ampli¢cation of cyclin D, which promotes
phosphorylation of pRB; loss of p16, a Cdk inhibitor which
inhibits the phosphorylation of pRB; or expression of the
HPV oncoprotein E7, which dissociates RB/E2F complexes
[4].
Based on structure, transcriptional properties and associa-
tion with pocket proteins, the E2F family can be divided into
three distinct subgroups: E2F1, E2F2 and E2F3, E2F4 and
E2F5, and E2F6. E2F1, E2F2 and E2F3 associate exclusively
with pRB and are potent transcriptional activators. In con-
trast, E2F4, which associates with RB, p107 and p130, and
E2F5, which associates with p130, seem to be primarily in-
volved in the active repression of E2F-responsive genes [5].
E2F6 does not interact with pocket proteins and functions
as negative regulator of E2F-dependent transcription via com-
plexing with chromatin modi¢ers [6,7].
Exogenous expression of E2F1, E2F2 or E2F3 in quiescent
cells results in S-phase entry [8,9]. In addition, E2F1 has an
apparent unique ability to induce apoptosis. This review fo-
cuses on E2F1-induced apoptosis. For recent reviews discus-
sing other biological functions of E2F family members see
[5,10].
2. E2F1 induces apoptosis
A variety of experiments implicate E2F1 in induction of
apoptosis (reviewed in [11]): ectopic expression of E2F1 leads
to apoptosis in tissue culture cells [12^14] and transgenic mice
[15^17]. A physiological role for E2F1-mediated apoptosis is
suggested by the observation that mice de¢cient in E2F1 have
an excess of mature T cells due to a defect in thymocyte ap-
optosis [18]. In addition, mice de¢cient in both Rb and E2F1
demonstrate signi¢cant suppression of both the aberrant ap-
optosis and the S-phase entry observed in mice carrying only
homozygous Rb mutation [19]. Similarly, inactivation of Rb
in mouse brain epithelium induces aberrant proliferation and
apoptosis that are inhibited by E2F1 de¢ciency [20], implicat-
ing E2F1 in Rb-dependent apoptosis. Interestingly, also E2F3
de¢ciency, but not E2F2 de¢ciency, suppresses the inappro-
priate apoptosis arising in the Rb mutant mice embryos, pro-
viding evidence for a role of E2F3 in the apoptosis that occurs
in the absence of Rb [21,22]. Ectopic expression of E2F2 and
E2F3 was reported to induce apoptosis in some experimental
systems [9] but not in others [8,23]. It remains to be deter-
0014-5793 / 02 / $22.00 D 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 2 7 0 - 2
*Fax: (972)-8-934 4125.
E-mail address: doron.ginsberg@weizmann.ac.il (D. Ginsberg).
FEBS 26496 17-9-02
FEBS 26496FEBS Letters 529 (2002) 122^125
mined whether the observed E2F2 and E2F3-induced apopto-
sis is E2F1-dependent.
The induction of apoptosis by E2F1, as for c-Myc, is ab-
rogated by growth factors [12]. In fact, the ability of Myc to
induce apoptosis is E2F1-dependent and is markedly reduced
in cells deleted for E2F1 [24].
Experiments using tissue culture cells as well as transgenic
mice demonstrate that E2F1-induced apoptosis is mediated by
both p53-dependent [12,13,25] and p53-independent [16,26]
pathways.
3. The role of p53 in E2F1-induced apoptosis
Ectopic expression of E2F1 induces p53 accumulation
[14,27] and one mechanism underlying this phenomenon is
the direct transactivation of the p14ARF tumor suppressor
gene (p19ARF in rodents) by E2F1 [28,29]. ARF interacts
with the Mdm2 E3 ubiquitin ligase, and inhibits the ability
of mdm2 to target p53 to ubiquitination and subsequent deg-
radation [30]. Thus, the E2F1-induced increase in ARF levels
leads to p53 stabilization and activation.
In addition, E2F1 increases p53 levels and p53-dependent
apoptosis also in the absence of ARF, suggesting the existence
of additional, ARF-independent, functional links between
E2F1 and p53. A number of recent studies demonstrate that
RB inactivation or E2F1 over-expression leads to apoptosis
that is inhibited by loss of p53 but not by loss of ARF [31^
33]. In fact, in some cases loss of ARF even enhances E2F1-
induced apoptosis [31,33]. This enhancement is in agreement
with the ability of ectopically expressed ARF to inhibit E2F1-
induced apoptosis [34] and target E2F1 to degradation [35].
E2F1-induced apoptosis in the absence of ARF was shown
to correlate with p53 phosphorylation at residues that are also
phosphorylated in response to DNA damage [31,36]. Induc-
tion of both apoptosis and p53 phosphorylation by E2F1 are
abolished by ca¡eine, an inhibitor of the ATM and ATR
protein kinases ([36] and D. Johnson, personal communica-
tion). These data implicate kinases of the ATM family in
E2F1-mediated apoptosis. However, the mechanism govern-
ing their activation by E2F1 remains to be determined.
E2F1 interacts with p53 and a recent study demonstrates
that this interaction occurs via the cyclin A binding domain of
E2F1 and enhances the apoptotic activity of p53 [37]. This
function of E2F1 does not require DNA binding or transcrip-
tional activity and it is shared by E2F2 and E2F3 [37].
Taken together, the existing data strongly suggest that
E2F1 a¡ects p53-dependent apoptosis through a number of
pathways. One of these pathways involves activation of ARF,
another relies on physical interaction with p53, while yet an-
other is ca¡eine-sensitive. The exact nature of the two latter
mechanisms awaits further studies.
4. Additional pathways mediating E2F1-induced apoptosis
The p53 homolog p73 also plays a role in E2F1-induced
apoptosis. E2F1 directly activates transcription of p73, lead-
ing to activation of p53-responsive target genes and apoptosis
[38,39]. Disruption of p73 function, by dominant negative p73
mutants or gene targeting, inhibits E2F1-induced apoptosis
[38,39].
Stimulation of the T-cell receptor (TCR) on mature T cells
causes their apoptosis by a process called TCR-activation-in-
duced cell death (TCR-AICD). E2F1 and p73 are required for
TCR-AICD, which is a physiological and naturally occurring
apoptotic process [40]. However, although E2F1 is clearly
involved in AICD, it has not been demonstrated whether it
is required for induction of p73 in this process.
E2F1 also directly activates the expression of the Apaf-1
gene encoding for apoptosis protease-activating factor 1
[41,42]. When induced, ApafI assembles with cytochrome c,
a mitochondrial protein released upon apoptotic signals, and
activates procaspase 9, leading to the activation of down-
stream e¡ector caspases, including caspase-3, caspase-6 and
caspase-7. Induction of E2F1 activity results in an increase
of mRNA and protein levels of ApafI and a concomitant
activation of caspases-9, -3, -6 and possibly also caspase-7
[41,42]. E2F1-induced apoptosis is signi¢cantly reduced by
inhibitors of caspase activity or by gene disruption of ApafI,
indicating that the E2F1/ApafI/caspases pathway is an impor-
tant mediator of E2F1-induced apoptosis [41,42]. Additional
support for this notion comes from the study of RB null mice.
RB3=3 embryos exhibit increased levels of ApafI [41] and
analysis of compound mutants lacking both Rb and ApafI
demonstrates that ApafI is required for apoptosis induced
by RB de¢ciency in some but not all tissues [43].
ApafI is a direct transcriptional target of p53 [41], raising
the possibility that its transactivation by E2F1 is indirect.
However, this is most probably not the case, since E2F1 acti-
vates deleted versions of the ApafI promoter that are not
activated by p53 [41]. Furthermore, E2F1 binds the ApafI
promoter and transactivates the ApafI gene in cells lacking
p53 [42].
Increased E2F1 activity also results in release of cyto-
chrome c from mitochondria to the cytoplasm. However,
such release has been observed only in cell lines with wt p53
but not in a cell line lacking functional p53 [41,42], and the
mechanism underlying E2F1-induced cytochrome c release
has not been elucidated yet.
DNA microarray studies demonstrate that ectopic expres-
sion of E2Fs up-regulates expression of pro-apoptotic mem-
bers of the Bcl-2 family, including Bok, Bad, Bak and Bid1
[44^46]. The validity of these DNA microarray data and the
importance of these pro-apoptotic genes in E2F1-induced ap-
optosis are currently being studied. In addition, DNA micro-
array analysis indicates that ectopic expression of E2Fs up-
regulates expression of caspase-3 and caspase-7 [44,47], and a
recent study demonstrates that E2F1 directly regulates the
expression of several members of the caspase family (S.
Lowe, personal communication).
Interestingly, studies using E2F1 mutants demonstrate that
although its DNA-binding activity is required, transcriptional
transactivation is not necessary for the induction of apoptosis
by E2F1 [26,48]. These observations indicate that alleviation
of E2F-dependent transcriptional repression contributes to
E2F1-induced apoptosis. Additional studies are required to
determine whether E2F1-mediated repression or activation
regulate expression of speci¢c apoptosis-related genes.
5. E2F1 inhibits anti-apoptotic signals
Another mechanism by which deregulated E2F1 triggers
apoptosis and sensitizes cells to pro-apoptotic stimuli involves
disruption of NF-UB signaling [49,50]. The NF-UB transcrip-
tion factor is a major regulator of cell survival and its induc-
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tion in response to death-promoting stimuli confers resistance
to apoptosis. The anti-apoptotic activity of NF-UB is medi-
ated by transcriptional activation of various anti-apoptotic
genes (reviewed in [51]).
E2F1 was shown to down-regulate TRAF2 protein levels,
thus leading to impaired TNF-receptor-mediated NF-UB and
JNK activation in response to TNFK [49]. The molecular
basis for this down-regulation of TRAF2 protein levels re-
mains unclear but it does not require E2F1-dependent trans-
activation, since this e¡ect is exerted also by a transactivation-
de¢cient mutant of E2F1 [49].
Rel family proteins dimerize to form the functional NF-UB
transcription factor [51] and a recent study showed that E2F1
competes with p50 for RelA/p65 binding, thus inhibiting NF-
UB DNA binding activity [50]. These data provide another
mechanism for E2F1-mediated inhibition of NF-UB activity.
6. E2F1 sensitizes cells to apoptotic stimuli
Overexpression of E2F1 in a variety of cell types sensitizes
cells to apoptosis when they are treated with ionizing radia-
tion or chemotherapeutic drugs such as the topoisomerase II
inhibitors, etoposide and adriamycin [52,53]. A direct role for
E2F1 in the response to DNA damage is suggested by its up-
regulation after DNA damage [54^56]. This stress-induced
increase in E2F1 protein levels is due to protein stabilization
that is mediated by an ATM-induced phosphorylation [57].
However, it is not clear whether the stress-induced E2F1 is
transcriptionally active. It does not transactivate a number of
known E2F targets [56] and it remains to be determined
whether it can regulate expression of apoptosis-related genes.
Thus, the molecular mechanism(s) underlying the ability of
E2F1 to sensitize cells to apoptotic stimuli are currently not
fully understood. Nevertheless, it is well established that the
pRB pathway is functionally inactivated in most human can-
cers, leading to deregulated E2F activity. Therefore, the abil-
ity of E2F1 to sensitize cells to death in response to genotoxic
stress might play an important role in the increased sensitivity
of tumor cells to chemo- and radiotherapy.
Overall, the induction of apoptosis by deregulated E2F1 is
by now well established and the studies discussed above pro-
vide a number of pathways mediating this activity (Fig. 1).
Nevertheless, a number of key questions are still unanswered.
Most probably we do not yet have the full spectrum of apo-
ptosis-related genes that are regulated by E2F1. The large-
scale screens for E2F-regulated genes provide new and inter-
esting possible links between E2F1 and apoptotic pathways
that will undoubtedly be followed by detailed studies and will
provide novel insights into the apoptotic potential of E2F1.
Additional issues that require further elucidation include the
role of E2F3 and the importance of E2F-mediated transcrip-
tional repression in apoptosis. Importantly, keeping in mind
the pivotal role of the E2F family in regulating cell prolifer-
ation, it is imperative to better understand the mechanism(s)
determining whether the ¢nal outcome of E2F activity will be
proliferation or death.
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